#United States #California #Class Action #Pomerantz Law #Jasper Therapeutics

Pomerantz Law Firm's Class Action Against Jasper Therapeutics

The Pomerantz Law Firm has announced the filing of a class action lawsuit against Jasper Therapeutics, Inc. and some of its key executives. The lawsuit, initiated in the United States District Court for the Northern District of California, pertains to claims made by investors who acquired Jasper securities during a specified period from November 30, 2023, to July 3, 2025. The legal action alleges violations of federal securities laws, asserting that Jasper and its officers made materially false statements and failed to disclose critical information regarding the company's operations.

Background on Jasper Therapeutics

Jasper is a clinical-stage biotechnology company focused on developing treatments for conditions driven by mast cell activity, including Chronic Spontaneous Urticaria and various forms of asthma. The company's primary candidate, briquilimab, aims to target mast cells by blocking a key pathway essential for their survival. By advancing a number of clinical programs, Jasper has sought to establish itself as a leader in this niche market.

In 2024, Jasper announced a significant financial maneuver, securing $50 million from prominent life science investors. This financing aimed to bolster the company’s development efforts and was positioned as an extension of its financial runway. Additionally, the company launched its BEACON Study in late 2023, a Phase 1b/2a clinical trial focused on using briquilimab for treating Chronic Spontaneous Urticaria, which featured statements of confidence from Jasper’s CEO, Ronald Martell, regarding the execution of their plans.

Allegations of Misconduct

The lawsuit claims that throughout the designated Class Period, Jasper’s leadership failed to disclose that the company lacked adequate controls over its manufacturing processes. This negligence reportedly heightened the risk of issues arising from ongoing studies, potentially jeopardizing the regulatory approval and market viability of briquilimab.

Specifically, the complaint highlights that Jasper relied on third-party manufacturers to produce its drug candidates but had insufficient oversight of those operations, which were supposed to comply with stringent good manufacturing practices (cGMP). Furthermore, investors allege that misleading statements inflated the perceived health of the company’s financial outlook and product development pipeline.

Impact of Recent Developments

On July 7, 2025, Jasper released troubling data from the BEACON Study, which indicated complications regarding a specific drug lot used in the trial. As a result, the company paused both the BEACON Study and related programs targeting asthma, significantly impacting stock prices. Following this announcement, Jasper’s share price plummeted by over 55%. Analysts quickly downgraded their assessments, reflecting growing concerns about the integrity of briquilimab’s trials and the overarching stability of the company's operations.

Legal Recourse for Investors

Currently, investors who acquired Jasper securities during the Class Period have until November 18, 2025, to formally request the Court appoint them as Lead Plaintiff. Interested parties are advised to contact Pomerantz LLP directly to discuss participation in the class action. The full details of the complaint can be accessed on the Pomerantz Law Firm’s website.

Pomerantz LLP boasts a long-standing history of advocacy in securities litigation, with an established reputation for championing the rights of shareholders. Investors facing losses due to the alleged mismanagement and misleading practices by Jasper Therapeutics may now have a potential pathway to recovery through this class action.

In conclusion, as the legal proceedings unfold, both Jasper Therapeutics and its investors face uncertain futures amid mounting scrutiny over their practices and the efficacy of their leading product, briquilimab.